Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategiesJustin N Bottsford-Miller, Robert L Coleman, Anil K Sood
Molecular Cancer Therapeutics|September 18, 2016
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian CancerYan Huang, Lenard M Lichtenberger, Morgan Taylor, et al.
Cancer Gene Therapy|March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancerRodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
The Lancet. Oncology|December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialRodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Targeting SRC in mucinous ovarian carcinomaKoji Matsuo, Masato Nishimura, Justin N Bottsford-Miller, et al.
Pageof 1